Great story Rose; Like the Movie "How It Ends." the gas station scene with Forest Whitaker.
There's all kinds of scams out there too. Offerup, Craigslist,
Random thoughts today; trying to stay focused on why we are here and why we're invested in Amarin. What a wonderful drug we have, yet Amarin Management has relatively given up on the US market. They refuse to do anything constructive. I really think they don't know what to do quite frankly. Vascepa needs to be in the hands of someone who can and will exploit the uses for this wonderful drug.
Mitigate Clinical Trial: Brief Summary:
MITIGATE is a prospective, open-label, parallel-group, randomized, pragmatic clinical trial. The MITIGATE Study has been designed to evaluate the real-world clinical effectiveness of pre-treatment with icosapent ethyl (IPE), also known as Vascepa®, compared to usual standard of care to prevent and reduce the sequelae of laboratory-confirmed viral upper respiratory infection (URI)-related (i.e., COVID-19, influenza, and other known viral respiratory pathogens) morbidity and mortality in a high-risk cohort of adults with established atherosclerotic cardiovascular disease (ASCVD). Status?
Effects COVID-19 had on world population; Around 7.46 million excess deaths occurred on average in both 2020 and 2021, leading to nearly 15 million excess deaths over the two-year period. Excess deaths measure the difference between the number of actual deaths and the number of deaths that would have been expected had the pandemic not occurred.
Brave Clinical Trial:Brief Summary:
This is an open-label, placebo run-in study to investigate the genetic and biomedical predictors of blood pressure response to bisoprolol. After informed consent is obtained, subjects will be withdrawn from previous antihypertensive therapy and given placebo for at least 2 weeks. Compliance will be assessed using pill counting, and any subject will a compliance less than 80% during the placebo run-in period will be excluded from the study. Bisoprolol 2.5 mg will be given once daily for 6 weeks. At baseline and after 6 weeks on bisoprolol 2.5 mg the clinic sitting blood pressure, 24-hour ambulatory blood pressure (if the patient is willing to do this), clinical characteristics and biochemical profile will be measured. Central aortic blood pressure will be measured with the A-PULSE device at baseline and after 6 weeks treatment.
After completing 6 weeks treatment with bisoprolol 2.5 mg daily, the patient will continue treatment with bisoprolol for a total of 24 weeks unless there is any adverse event that requires discontinuation of bisoprolol.Status?
Alzheimer's impact on the world. Worldwide, at least 50 million people are believed to be living with Alzheimer's disease or other dementias. According to the United Nations, that is more than the population of Colombia. If breakthroughs are not discovered, rates could exceed 152 million by 2050.
WHAT IS FIBROMYALGIA?
Fibromyalgia is a condition that causes ongoing pain throughout the body. It's characterized by numerous tender points all over the body. Symptoms of Fibro include muscle and joint stiffness, depression, anxiety, sleep problems, fatigue, brain fog, memory issues, headaches, numbness/tingling in extremities and digestive issues. Central sensitization is thought to be the primary mechanism involved. This is where the central nervous system gets regulated into a persistent state of high reactivity which can create extreme pain even with minimal stimulus.
Abstract: Fibromyalgia syndrome (FMS) is a chronic musculoskeletal disorder of unknown etiology that affects up to 5.0% of the world population (8 Billion or approx. 400 Million people are afflicted with Fibromyalgia). It has a high female predominance, between 80 and 96%. Due to the low number of diagnosed men, research work has focused mainly on women. So, these figures did not include all men.
Top four treatments for Fibromyalgia; Painkillers, Muscle relaxants, Anti-depressants (cannabis), Sleeping pills.....
No wonder Humira is the number #1 selling drug in the world.
Rank Drug Main indication Trade name 2015 2016 2017 2018 2019
1 adalimumab rheumatoid arthritis Humira 10.1 13.5 16.3 18.4 21.4
2 apixaban anticoagulant Eliquis 1.6 3.0 4.6 7.1 9.9
3 etanercept rheumatoid arthritis Enbrel 7.2 7.6 7.9 8.0 8.1
4 ustekinumab psoriasis Stelara 2.0 2.6 3.7 5.0 6.6
5 pembrolizumab oncology Keytruda 0.4 0.7 2.2 4.3 6.5
